The Effect of Thalidomide in Suppression of the Systemic Inflammatory

Status Terminated

Clinical Trial Summary

Both malnutrition and inflammation are associated with death in dialysis patients and also with cardiovascular disease. The researchers are testing the idea that inflammation causes malnutrition by using a drug to suppress inflammation in hemodialysis patients to find out whether that will increase blood tests that are associated with malnutrition. The researchers will give hemodialysis patients who have both inflammation and malnutrition either thalidomide or a placebo and compare the effects of treatment on the levels of two proteins in the blood, albumin and prealbumin, that are normally reduced in malnourished patients. Patients who have a serum albumin concentration < 3.8 g/dl will be asked to sign consent to have blood drawn prior to dialysis for measurement of CRP (C-reactive protein). Those with CRP values ≥ 0.8 mg/dl will have a second measurement of CRP performed within 2 weeks. Those with two consecutive values of CRP ≥ 0.8 mg/dl will be eligible for enrollment

Clinical Trial Description

4.1 Pre-assignment measurements will include:

1. Patient is eligible for enrollment.

2. Complete physical examination.

3. Blood draw at initiation of hemodialysis session

4. Instruction on birth control methods required.

5. Subjects who are non-compliant with regard to medication compliance range or birth control requirements as outlined in the S.T.E.P.S.® program will be immediately discontinued from the study

4.2 Detailed description of treatment: Patients who completed the first 4 weeks will be randomized into Treatment group. A total of 24 subjects will be studied; 12 will receive no drug and 12 will receive thalidomide. Subjects randomized to "Active" Treatment arm will receive Placebo (no-drug/sugar pill) ,or thalidomide 100 mg (two 50 mg active capsules) to take at bedtime. Weekly, Subjects will have blood drawn; will undergo a capsule count to establish a compliance range of > 85%; will have physical exam with special attention to skin and evaluation of peripheral nervous system for a change in or appearance of sensory neuropathy.

If somnolence is tolerable (subjects do not have residual somnolence in the morning) the dose will be increased to 200 mg (4 capsules).

Patients who completed 24 weeks of study will have final evaluation at week 28. ;

Study Design

Related Conditions & MeSH terms

Hypoalbuminemia
Systemic Inflammatory Response Syndrome

Clinical Trial Details

NCT number	NCT00529633
Study type	Interventional
Source	University of California, Davis
Contact
Status	Terminated
Phase	Phase 3
Start date	September 2007
Completion date	December 2009

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05050851` - Nutritional Parameters and Other Risk Factors Affecting Severity of Pneumonia in Children Under Five Years in Upper Egypt
Active, not recruiting	`NCT03675906` - The Relationship Between Hypoalbuminemia and Development of Acute Kidney Failure (AKI) According to KDIGO Criteria
Terminated	`NCT04071041` - Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.	Phase 3
Completed	`NCT03569410` - The Effect of Natural Protein vs. Protein Supplements on Peritoneal Dialysis Patients	N/A
Terminated	`NCT02457702` - Mitochondrial Function in Patients With Severe Liver Disease	N/A
Active, not recruiting	`NCT02288494` - Acid Base Balance of ICU Patients With Severe Hypoalbuminemia, Before and After an Albumin Infusion, Using Stewart Approach	N/A
Completed	`NCT02765061` - Hyponatremia and Hypoalbuminemia is Morbimortality Predictors in Coronary Artery Bypass Graft Surgery	N/A
Completed	`NCT03167645` - SUbstition of PERioperative Albumin Deficiency Disorders	Phase 4
Recruiting	`NCT05797649` - Comparing N-terminal-proB-type Natriuretic Peptide With Other Criteria in Pleural Fluid Analysis
Completed	`NCT01822600` - The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia	Phase 4
Completed	`NCT01542749` - Total Body Albumin Measurement Utilizing a Modification of the BVA 100 Blood Volume Analyzer	N/A
Completed	`NCT00723762` - Valproic Acid-associated Hypoalbuminemia in Medically Fragile Patients	N/A
Completed	`NCT00561093` - Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients	Phase 3
Completed	`NCT04046263` - Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients	Phase 4
Completed	`NCT00597025` - Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin	N/A
Completed	`NCT06355479` - A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients — ICM

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms